
Paradise™ uRDN System Delivers a 19.5 mmHg Reduction in Blood Pressure at 12 Months, With Sustained Benefits for Up to Four Years
Recor Medical, Inc. (Recor), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., has announced encouraging new clinical findings demonstrating the effectiveness and long-term safety of its Paradise™ Ultrasound Renal Denervation (uRDN) System in patients with uncontrolled hypertension. The latest results from the Global Paradise™ System (GPS) Registry highlight clinically meaningful reductions in blood pressure following treatment, providing additional real-world evidence supporting the use of ultrasound renal denervation as a treatment option for patients whose blood pressure remains inadequately controlled.
The findings were presented at the 2026 Transcatheter Cardiovascular Therapeutics (TCT) congress as part of the conference’s “Best of Endovascular Abstracts” session. Recor sponsored a total of seven scientific abstracts at the congress, covering a range of clinical evidence, including real-world outcomes from European and U.S. clinical practice, as well as long-term efficacy data demonstrating sustained blood pressure reductions for up to four years.
The presentations further expand the growing clinical evidence supporting the Paradise uRDN System and its potential role in addressing uncontrolled hypertension. The findings highlight the system’s performance across different patient populations and clinical settings, while providing additional information about procedural safety, long-term outcomes and the durability of blood pressure reductions following renal denervation.
Hypertension remains a major global cardiovascular health challenge, with many patients continuing to experience elevated blood pressure despite receiving antihypertensive medications. For individuals with difficult-to-control or resistant hypertension, additional treatment approaches may be needed to achieve and maintain appropriate blood pressure levels. In this context, renal denervation is being investigated as a complementary approach designed to address the sympathetic nervous system activity involved in blood pressure regulation.
Global Paradise System Registry Demonstrates Significant Blood Pressure Reductions
One of the key presentations at TCT 2026 focused on 12-month outcomes from the Global Paradise System Registry. The study, titled “Blood Pressure Outcomes Following Ultrasound Renal Denervation in Uncontrolled Hypertension: 12-Month Results from the Global Paradise System Registry,” was presented by Professor Felix Mahfoud, MD.
The analysis evaluated 276 patients with uncontrolled hypertension who were treated with the Paradise uRDN System across nine European countries. The registry was designed to assess the system’s performance in routine clinical practice, providing real-world information on blood pressure outcomes and safety beyond the controlled environment of randomized clinical trials.
The results demonstrated a substantial reduction in office systolic blood pressure following treatment. At the 12-month follow-up, patients experienced an average reduction of 19.5 mmHg in office systolic blood pressure, indicating a meaningful improvement in blood pressure control.
An even greater reduction was observed among patients with a history of hypertensive crises. In this subgroup, office systolic blood pressure decreased by 22.0 mmHg after 12 months. These findings are particularly relevant because patients with a history of hypertensive crises represent a population with significant clinical needs and challenges in achieving sustained blood pressure control.
The analysis also showed that 50% of patients achieved a blood pressure reduction of at least 15.0 mmHg. This finding indicates that a considerable proportion of patients experienced substantial improvements following ultrasound renal denervation.
In addition to the observed reductions in blood pressure, the registry demonstrated a favorable safety profile. The findings supported the safety of the Paradise uRDN procedure and its clinical outcomes during the 12-month observation period.
Commenting on the results, Professor Felix Mahfoud, co-principal investigator of the GPS Registry at University Hospital Basel, emphasized the importance of real-world evidence in understanding the clinical value of renal denervation.
He noted that the 12-month findings provide compelling real-world evidence supporting both the safety and effectiveness of the Paradise uRDN System. According to Professor Mahfoud, the magnitude of blood pressure reduction observed in routine clinical practice is clinically significant, particularly among patients with a history of hypertensive crises, who continue to represent a population with considerable unmet medical needs.
The findings reinforce the potential value of ultrasound renal denervation in clinical settings where conventional approaches may not consistently provide adequate blood pressure control.
U.S. Real-World Experience Shows Favorable Clinical Outcomes
Additional evidence presented at TCT 2026 highlighted the performance of the Paradise uRDN System in U.S. clinical practice. The presentation, titled “Sustained Blood Pressure Reduction, High Clinical Success, and Favorable Safety Following Ultrasound Renal Denervation: A Multicenter US Experience,” was delivered by Behnam N. Tehrani, MD.
The multicenter analysis included 238 patients who underwent treatment with the Paradise uRDN System. The study evaluated clinical outcomes and procedural safety, providing further insight into how the technology performs across different healthcare institutions and patient populations in the United States.
The findings demonstrated favorable outcomes in terms of both procedural performance and safety. Among the patients included in the analysis, 58 had complete follow-up information available for the 12-month assessment.
In this subgroup, office systolic blood pressure decreased by 26.9 mmHg after 12 months of treatment. This reduction highlights the potential for substantial blood pressure improvements among patients undergoing ultrasound renal denervation in routine clinical practice.
The U.S. experience adds another important dimension to the growing body of evidence supporting the Paradise system. While randomized clinical trials provide controlled assessments of treatment efficacy and safety, real-world studies help demonstrate how medical technologies perform when used across different clinical environments.
The European GPS Registry and U.S. multicenter experience together provide additional information about the effectiveness of the Paradise uRDN System in geographically diverse populations. Both presentations reported favorable blood pressure outcomes, strengthening the evidence supporting ultrasound renal denervation as a potential approach for patients with uncontrolled hypertension.
Four-Year Clinical Data Demonstrate Durable Blood Pressure Reductions
Beyond the 12-month real-world findings, Recor also presented important long-term clinical evidence demonstrating sustained reductions in blood pressure for up to four years following ultrasound renal denervation.
The presentation, titled “Durable Blood Pressure Reduction Through 4 Years Following Ultrasound Renal Denervation: Pooled Data from the RADIANCE Trial Program,” was delivered by co-principal investigator Professor Ajay J. Kirtane, MD.
The pooled analysis included 293 patients treated with ultrasound renal denervation as part of the RADIANCE clinical trial program. The analysis incorporated data from three major studies: RADIANCE-HTN SOLO, RADIANCE II and RADIANCE-HTN TRIO.
These studies evaluated the Paradise uRDN System in patients with different levels of hypertension severity.
RADIANCE-HTN SOLO and RADIANCE II focused on patients with mild to moderate hypertension, while RADIANCE-HTN TRIO evaluated patients with uncontrolled, resistant hypertension. By combining data from these clinical studies, researchers were able to assess the durability of blood pressure reductions across a broader range of patients.
The four-year findings demonstrated that office systolic blood pressure had decreased by 14.9 mmHg following treatment with the Paradise uRDN System.
Importantly, the analysis showed that 92% of patients experienced either a reduction in blood pressure or a decreased need for antihypertensive medication after undergoing renal denervation.
This finding is particularly significant because long-term hypertension management often requires ongoing medication adjustments and multiple treatment approaches. The reduction in blood pressure or medication requirements observed in the pooled analysis suggests that the clinical benefits associated with ultrasound renal denervation may be maintained over an extended period.
The long-term safety findings were also encouraging. Researchers did not identify any new long-term safety concerns during the four-year follow-up period.
These results provide additional evidence regarding the durability of the Paradise uRDN System’s effects and address an important question for both physicians and patients considering renal denervation: whether improvements in blood pressure can be sustained over several years.
Professor Ajay J. Kirtane, Professor of Internal Medicine at Columbia University’s Vagelos College of Physicians and Surgeons and co-principal investigator, highlighted the importance of longer-term clinical evidence.
He explained that patients and physicians are increasingly interested in understanding outcomes following renal denervation over extended periods. He also described the sustained blood pressure reductions observed for up to four years after ultrasound renal denervation as encouraging evidence supporting the technology’s long-term potential.
The findings are particularly relevant as healthcare professionals continue evaluating the role of renal denervation within comprehensive hypertension management strategies.
Expanding Clinical Evidence for Ultrasound Renal Denervation
The seven Recor-sponsored abstracts presented at TCT 2026 represent a broader effort to expand the clinical evidence supporting the Paradise uRDN System.
The presentations covered multiple aspects of the technology, including real-world effectiveness, procedural safety, clinical outcomes in different patient populations and the long-term durability of blood pressure reductions.
The GPS Registry provides evidence from patients treated in routine European clinical practice, while the multicenter U.S. analysis offers additional insights from American healthcare settings. Meanwhile, the pooled RADIANCE trial analysis contributes longer-term information from patients followed for up to four years.
Together, these findings provide a more comprehensive understanding of the Paradise system’s potential clinical benefits.
Real-world registry data are especially valuable because they help researchers assess treatment performance in broader patient populations, including individuals who may have different clinical characteristics from those enrolled in randomized controlled trials.
Similarly, long-term follow-up data are essential for evaluating whether the effects of a treatment remain consistent over time and whether additional safety concerns emerge with extended use.
For patients with uncontrolled or resistant hypertension, these findings may help inform future discussions about treatment options and the potential role of device-based interventions alongside conventional antihypertensive therapies.
Recor Medical Highlights the Potential to Transform Hypertension Treatment
Commenting on the growing body of clinical evidence, Shon Chakrabarti, MD, Chief Medical Officer of Recor Medical, emphasized the importance of the latest findings in supporting ultrasound renal denervation.
According to Dr. Chakrabarti, the clinical evidence supporting renal denervation has become increasingly compelling. Both randomized clinical trials and real-world clinical practice have demonstrated significant and sustained blood pressure reductions across a broad spectrum of patients with uncontrolled hypertension.
He also highlighted that the latest findings strengthen the company’s confidence in the Paradise uRDN System and underscore the potential of renal denervation to influence the future treatment of hypertension.
The clinical results presented at TCT 2026 demonstrate meaningful blood pressure reductions across different patient populations, including individuals with a history of hypertensive crises and those with uncontrolled or resistant hypertension.
The findings also provide encouraging evidence regarding the system’s safety profile, with favorable procedural and clinical outcomes reported in real-world analyses and no new long-term safety concerns identified in the pooled four-year clinical data.
Advancing the Future of Hypertension Management
The latest GPS Registry and RADIANCE trial findings add to the expanding clinical evidence supporting the Paradise Ultrasound Renal Denervation System as a potential treatment option for patients with uncontrolled hypertension.
The 19.5 mmHg reduction in office systolic blood pressure observed in the European registry after 12 months, together with the 26.9 mmHg reduction reported in the U.S. multicenter experience among patients with complete follow-up data, demonstrates encouraging outcomes across real-world clinical settings.
Furthermore, the 14.9 mmHg reduction in office systolic blood pressure maintained through four years in the pooled RADIANCE analysis highlights the potential durability of treatment benefits. The finding that 92% of patients experienced either lower blood pressure or a reduced need for antihypertensive medication provides additional support for the long-term clinical relevance of renal denervation.
Although hypertension remains a complex condition requiring individualized treatment and ongoing monitoring, these findings contribute important evidence to the evaluation of device-based approaches for blood pressure management.
Through its continued clinical research and evidence-generation initiatives, Recor Medical aims to further establish the role of ultrasound renal denervation in cardiovascular care. The latest presentations at TCT 2026 represent another important step in understanding the safety, effectiveness and long-term potential of the Paradise uRDN System for patients who continue to face challenges achieving adequate blood pressure control.
About the Paradise™ uRDN system
The Paradise™ uRDN system is a novel, ultrasound-based renal denervation (RDN) technology that lowers blood pressure by denervating the sympathetic nerves surrounding the renal arteries. This reduces the overactivity that can lead to hypertension. With the Paradise™ uRDN system, two to three doses of 360-degree ultrasound energy—each lasting seven seconds—are delivered to the surrounding nerves via the main renal arteries. The Paradise™ catheter features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to protect the renal artery wall.
The Paradise™ uRDN System was named one of TIME magazine’s best inventions of 2026. It is currently commercially available in the U.S., having received FDA approval in November 2023. The Paradise™ Ultrasound Renal Denervation System (the Paradise™ System) is indicated as an adjunct to blood pressure lowering therapy in patients with hypertension whose blood pressure is not adequately controlled by lifestyle modifications and antihypertensive medications. The most common procedure-related adverse events that may occur include pain, vascular access complications, and vasospasm.
About Recor Medical, Inc.
Recor Medical, Inc., a wholly-owned subsidiary of Otsuka Medical Devices Co., Ltd., headquartered in Palo Alto, California, is a medical device company dedicated to advancing the treatment of treatment-resistant hypertension through the Paradise™ Ultrasound Renal Denervation (uRDN) System. The Paradise™ uRDN System is FDA-cleared for distribution in the United States, carries CE Mark 2797, and is approved in markets where CE Mark 2797 is recognized for its approved uses.
The system has also received regulatory approval in Japan. Clinical evidence for the Paradise™ uRDN System includes positive results from three independent, randomized, sham-controlled trials in patients with mild to moderate, treatment-resistant hypertension. Furthermore, Recor is expanding the evidence base from routine clinical care through the Global Paradise™ System (“GPS”) registry in the European Union and the United Kingdom, as well as through the US post-approval GPS study.



